Variant CE1 construct with BDFV HUH endonuclease, expressed from CMV or T7 promoters.

Variant CE1 construct with CoCV HUH endonuclease, expressed from CMV or T7 promoters.

Variant CE1 construct with FiCV HUH endonuclease, expressed from CMV or T7 promoters.

Variant CE1 construct with GuCV HUH endonuclease, expressed from CMV or T7 promoters.

Variant CE1 construct with PCV1 HUH endonuclease, expressed from CMV or T7 promoters.

A variant CE1 construct with Phi29 DNA polymerase (exo active), expressed from CMV or T7 promoters.

A variant CE1 construct with ePhi29 DNA polymerase (exo active), expressed from CMV or T7 promoters.

Variant CE1 construct with engineered M-MLV reverse transcriptase (RT; found in PE2), expressed from CMV or T7 promoters

Bacterial expression plasmid for SpCas9 + N497A/R661A/Q695A, HNH FRET variant

Plasmid encoding ADAR2dd attached to PUF-9R with deimmunizing and function-restoring mutations under control of CMV promoter with two TetR binding sites

Ready-to-use AAV1 particles produced from pGP-AAV-syn-jGCaMP7c variant 1513-WPRE (#105321). In addition to the viral particles, you will also receive purified pGP-AAV-syn-jGCaMP7c variant 1513-WPRE plasmid DNA. Synapsin-driven jGCaMP7c expression. jGCaMP7c exhibits high contrast between peak fluorescence and resting fluorescence. It is useful for activity imaging of large populations of densely-labeled neurons because background fluorescence from inactive neurons is reduced. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from pGP-AAV-syn-FLEX-jGCaMP7c variant 1513-WPRE (#105322). In addition to the viral particles, you will also receive purified pGP-AAV-syn-FLEX-jGCaMP7c variant 1513-WPRE plasmid DNA. Synapsin-driven, Cre-dependent jGCaMP7c expression. jGCaMP7c exhibits high contrast between peak fluorescence and resting fluorescence. It is useful for activity imaging of large populations of densely-labeled neurons because background fluorescence from inactive neurons is reduced. These AAV preparations are suitable purity for injection into animals.

Fluorescence activatable reporter of flavivirus NS2B-NS3 protease activity

Fluorescence activatable reporter of flavivirus NS2B-NS3 protease activity

Fluorescence activatable reporter of ZIKV NS2B-NS3 protease activity

Fluorescence activatable reporter of DENV-2 NS2B-NS3 protease activity

Transposon-based SARS-CoV-2 secretable trimeric Spike stable expression vector for protein production

Transposon-based SARS-CoV-2 RBD stable expression vector for protein production

3rd generation lentiviral bicistronic vector for mammalian expression of H2B-EGFP and one gene of interest

3rd generation lentiviral bicistronic vector for mammalian expression of H2B-mTagBFP2 and one gene of interest